In recent years, the retinitis pigmentosa market is anticipated to grow rapidly during the forecast period. According to researchers, a total of 30,000 to 50,000 people are suffering from retinitis pigmentosa. Because there is no cure for retinitis pigmentosa, most persons who are affected by the hereditary ailment move to the severe stage of the disease. It has, however, created an opening for new medicines and treatments. Manufacturers from the ophthalmology sector are currently investigating a novel strategy known as optogenetics, which includes gene therapy to restore vision. It aids the ability of cells, particularly ganglion cells, to respond to light following the degeneration of rod and cone cells.
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Autosomal Recessive, Autosomal Dominant, X-Linked), Treatment (Vitamin A, Docosahexaenoic acid (DHA), Calcium channel blockers, Gene therapy, Retinal eye prosthetics, Others), Route of Administration (Oral, Topical, Others), Diagnosis (Electroretinogram, Visual Field Testing, Genetic Testing, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Retinitis Pigmentosa Market size was valued at USD 14.29 USD Billion in 2024.
The Global Retinitis Pigmentosa Market is projected to grow at a CAGR of 7.3% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
